DoseAdvisor bridges the gap between the regimen you prescribe and what your patient does between appointments.
Most patients on insulin make their own dosing decisions between appointments — with a paper protocol, a vague memory, or nothing at all. Errors happen not from malice, but from ambiguity, math, and the absence of real-time guardrails.
DoseAdvisor was founded on a simple premise: the clinician should control the dosing logic, and the patient should be given a clear, safe, explainable answer — every time they check their blood glucose.
The platform is a product of GlucoWorks LLC, designed and developed by a board-certified endocrinologist with deep experience in insulin management and clinical informatics. GlucoWorks is pursuing FDA Clinical Decision Support (CDS) designation, with a randomized controlled trial currently being implemented as the clinical evidence foundation.
The regimen prescription is the communication. Not a text message. Not a phone call. The structured, safe, clinician-configured protocol the patient carries with them.
— DoseAdvisor Design PrincipleEvery dosing parameter is set by the prescribing clinician. The app enforces those parameters — it cannot be overridden or second-guessed by the patient or the algorithm.
IOB tracking, dose caps, BG thresholds, and confirmation prompts exist because clinical practice demands them. No feature is sacrificed for simpler UX.
Every calculation is explained step-by-step to the patient. No black box. The patient understands exactly what the app calculated and why.
Every dose calculation is immutably logged. Clinicians can review exactly what their patient calculated, when, and under what parameters.
The platform is being built for FDA Clinical Decision Support (CDS) designation from the ground up. Architecture decisions reflect this — not just product convenience.
Designed for clinic and payer adoption — enabling CPT-based RPM billing for endocrinology practices. Future roadmap includes a B2C channel for HSA-eligible self-payers.
DoseAdvisor is pursuing FDA Clinical Decision Support (CDS) designation. The platform is being built to meet the applicable regulatory criteria for software-based clinical decision support from the outset.
Before broad commercialization, we are pursuing a randomized controlled trial to generate clinical evidence of superiority over standard of care. A grant application has been submitted to fund the trial, and all commercialization decisions are sequenced after its completion.
Core platform built and validated with 102+ unit tests across the dose calculation engine. Grant application submitted to fund a randomized controlled trial establishing clinical evidence.
Trial data captures clinical outcomes and health economic endpoints. Results are structured to support the FDA CDS designation application and payer value arguments simultaneously.
FHIR R4 adapter layer enables integration with major EHR platforms. Deployment to endocrinology practices and health systems through institutional partnerships.
B2B clinic deployment with CPT-based Remote Patient Monitoring billing enablement for endocrinology practices. Future roadmap includes HSA-eligible B2C channel and national expansion.
We're seeking clinical collaborators, institutional partners, and early adopter practices for our clinical trial and beyond.
Tell us about your practice or institution — we'll be in touch.
We respond within 2 business days. Your information is never shared.